Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 13/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31318812 | 1.00 | RET (0.45) | RETJAK3BTKPTPN11GPR119 | |
| SCHEMBL16926355 | 0.87 | PTPN11 (0.43) | RETPTPN11 | |
| SCHEMBL22389959 | 0.85 | PTPN11 (0.39) | RETPTPN11 | |
| SCHEMBL23508886 | 0.84 | RET (0.45) | RETJAK3BTK | |
| SCHEMBL22389965 | 0.83 | RET (0.40) | RETJAK3BTK | |
| SCHEMBL22389885 | 0.83 | RET (0.38) | RETPTPN11 | |
| SCHEMBL30005349 | 0.82 | PTPN11 (0.51) | RETPTPN11 | |
| SCHEMBL28667431 | 0.82 | PTPN11 (0.51) | RETPTPN11 | |
| SCHEMBL26633607 | 0.82 | RET (0.39) | RETJAK3BTK | |
| SCHEMBL23500612 | 0.82 | RET (0.46) | RETJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| US-20220362244-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| CN-113795483-A | Carboxamide-pyrimidine derivatives as SHP2 antagonists | 默克专利有限公司 | 2021-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | PTPN5, PTPN2, PTPN1 | RET 60/4885JAK3 74/4885BTK 61/4885 |
| US-20220362244-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | PTPN5, PTPN2, PTPN1 | RET 60/4885JAK3 74/4885BTK 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.